Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Merck & Co.

Tracked across 51 events · 2266 articles · First seen Feb 12, 2025 · Last active Sep 23, 2026

Sentiment
19
Attention
8
Events
51
Relationships
64
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 80
Regulatory
Impact: Developer and manufacturer of Lipfendra; approval boosts its cardiovascular pipeline and revenue prospects.
Jul 16, 2026 · 93 articles
7 85
Tech
On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, combined with Merck's immunotherapy Pembrolizumab, met its primary and secondary endpoints in a Phase 3 trial involving 1,137 patients…
Impact: Merck co-developed the vaccine and markets Pembrolizumab, which is combined with intismeran. The trial success strengthens Merck's oncology franchise and provides a growth avenue as Pembrolizumab faces patent expiration later this decade.
Aug 19, 2026 · 126 articles
6 20
Regulatory
Impact: Merck & Co. struck a deal to cut prices, committing to sell its diabetes drugs Januvia, Janumet, and Janumet XR at 70% off list prices directly to US consumers and pledging $70 billion in US R&D and manufacturing investments.
Dec 19, 2025 · 7 articles
4 60
Business
Impact: MSD (Merck & Co., Inc., Rahway, New Jersey, USA) is partnering with the United Arab Emirates — Department of Health – Abu Dhabi (DoH)>>> to create a regional logistics hub, which will enhance its product distribution and market access in the region.
Jun 24, 2026 · 7 articles
6 -30
International
Impact: Merck & Co. is under investigation by the United States — House Select Committee on the Chinese Communist Party for its clinical trials in China, particularly in China — Xinjiang and at military hospitals, raising concerns about national security and ethics. This exposes Merck & Co. to potential reputational damage and regulatory scrutiny.
Apr 20, 2026 · 8 articles
4 60
Business
Impact: Merck & Co. is collaborating with The Hashgraph Association to integrate its M-Trust physical authentication technology, aiming to meet EU product transparency regulations and enhance its supply chain solutions.
Jun 09, 2026 · 7 articles
4 50
Business
Impact: Merck & Co., through its subsidiary MSD, will provide pembrolizumab (Pembrolizumab) for the Phase Ib clinical trial. This collaboration expands the potential applications of Pembrolizumab and strengthens its market position.
May 26, 2026 · 6 articles
6 60
Tech
Impact: As the manufacturer of pembrolizumab (Keytruda), Merck & Co.>>> benefits from the combination therapy's success, as it reinforces the drug's role as a standard of care and expands its potential market in combination with intismeran. The positive results could lead to continued strong sales for pembrolizumab.
Jun 01, 2026 · 6 articles
6 60
Tech
Impact: As the licensee for sac-TMT outside Greater China, the positive clinical trial results for sac-TMT in combination with its drug pembrolizumab (KEYTRUDA) validate its investment and expand its oncology portfolio.
May 30, 2026 · 14 articles
6 70
Tech
Impact: Merck & Co. is the manufacturer of pembrolizumab and reached a commercial agreement with United Kingdom — National Health Service England, leading to the drug's approval and availability.
Jun 25, 2026 · 6 articles
2 40
Business
Impact: Merck & Co. is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
4 60
Regulatory
Impact: Merck & Co. is the developer of Pembrolizumab, and the expanded FDA approval of the companion diagnostic test will likely increase the patient pool for its anti-PD-1 therapy.
Jun 02, 2026 · 7 articles
6 -20
Domestic
Impact: Manufacturer of the MMR vaccine, stated no scientific benefit to splitting it. Faces potential regulatory and market pressure if separate vaccines are developed, but currently no immediate financial impact.
Aug 10, 2026 · 266 articles
4 -25
Tech
Akeso announced that a pre-specified interim analysis of overall survival (OS) in the Phase III HARMONi-2 (AK112-303) trial, assessed by the Independent Data Monitoring Committee, met the key secondary OS endpoint. Ivonescimab, Akeso's first-in-class PD-1/VEGF…
Impact: Merck's pembrolizumab (Keytruda) is the comparator that ivonescimab beat on both OS and PFS, a competitive threat to its first-line NSCLC franchise.
Jul 20, 2026 · 6 articles
2 10
Tech
Moderna announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology Congress 2026, to be held October 23-27 in Madrid,…
Impact: Merck co-develops intismeran autogene with Moderna, so successful data would validate its mRNA oncology collaboration and pembrolizumab combination strategy.
Sep 21, 2026 · 6 articles
8 30
Tech
Impact: Merck & Co.>>>'s immunotherapy Keytruda is mentioned as potentially faring better when patients are also taking GLP-1 drugs, suggesting a possible interaction with the immune system.
Jun 02, 2026 · 45 articles
4 50
Business
Impact: Merck & Co. is a prominent company in the maleic anhydride market, influencing its development and growth.
Jun 02, 2026 · 7 articles
8 20
Accidents
Impact: Merck & Co. is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
May 15, 2026 · 446 articles
4 30
Tech
Impact: Merck's Keytruda is used in combination with paxalisib in the planned trial; positive data could expand Keytruda's use in MSS/pMMR colorectal cancer, though the impact is indirect.
Jul 20, 2026 · 7 articles
4 20
Regulatory
Impact: Merck & Co. benefits from the expanded label of the VENTANA MMR RxDx Panel as it identifies patients eligible for its Pembrolizumab therapy, potentially increasing the drug's market reach.
Jun 11, 2026 · 6 articles
2 10
Business
Impact: Merck is participating in the Kinaxis conference as a speaker, sharing insights on navigating disruption and improving operational outcomes in supply chain management.
May 28, 2026 · 6 articles
2 5
Regulatory
India has crossed 80 lakh (8 million) Human Papillomavirus (HPV) vaccine doses administered under the National HPV Vaccination Campaign, the Bangladesh — Ministry of Health and Family Welfare said on Friday. The campaign was launched…
Impact: Merck manufactures Gardasil-4, the single-dose vaccine used free of cost in the campaign, supporting volume demand though at government procurement terms.
Sep 11, 2026 · 20 articles
1 5
Regulatory
India — Maharashtra is developing the India — Maharashtra Impact and Innovation Hub, a state-scale platform for health innovation and quality improvement. The initiative advances the Government of India — Maharashtra's Health for All goal…
Impact: Merck & Co. is the parent company of Merck & Co., indirectly associated with the initiative through its philanthropic arm's support.
Sep 16, 2026 · 6 articles
2 50
Business
Impact: Merck & Co. saw its stock price rise, contributing to the gains in the Dow Jones Industrial Average.
May 20, 2026 · 12 articles
8 10
Accidents
Impact: Merck & Co.>>>'s Ervebo vaccine, effective against the Zaire strain of Ebola, is being considered for potential use against the Uganda — Bundibugyo strain, though its efficacy is still under assessment.
May 18, 2026 · 505 articles
6 40
Tech
Impact: Merck & Co.'s approved vaccine Ervebo for the Zaire strain of Ebola is referenced as a technological precedent for IAVI's Bundibugyo vaccine candidate.
May 22, 2026 · 36 articles
6 0
Tech
Impact: Merck & Co. developed Ervebo, the only licensed Ebola vaccine, which the World Health Organization reviewed but recommended against deploying outside research settings for the Bundibugyo strain due to limited evidence.
May 28, 2026 · 6 articles
2 5
Business
Impact: Merck is mentioned as the former employer of Paul Reichert, highlighting its role in pharmaceutical innovation.
Jul 08, 2026 · 6 articles
7 70
Domestic
Impact: Merck jumped 9.7% following the positive cancer vaccine data, boosting its outlook.
Aug 19, 2026 · 133 articles
2 5
Business
The 2026 World Manufacturing Convention was held in Hefei, China — Anhui Province, China, from September 20 to 23, under the theme Intelligent Manufacturing for a Better Future. The event was jointly hosted by the…
Impact: Merck & Co. attended the convention, showcasing its presence in the manufacturing sector and exploring partnerships.
Sep 18, 2026 · 18 articles
+ 21 more events View on Dashboard
Amgen ↔ Merck & Co.
Amgen ↔ Merck & Co.
Merck Group ↔ Merck & Co.
Merck Group ↔ Merck & Co.
Tom Ksiazek ↔ Merck & Co.
Tom Ksiazek ↔ Merck & Co.
GSK plc ↔ Merck & Co.
GSK plc ↔ Merck & Co.
Sanofi ↔ Merck & Co.
Sanofi ↔ Merck & Co.
Moderna ↔ Merck & Co.
Moderna ↔ Merck & Co.
Gilead Sciences ↔ Merck & Co.
Gilead Sciences ↔ Merck & Co.
GAVI ↔ Merck & Co.
GAVI ↔ Merck & Co.
AstraZeneca ↔ Merck & Co.
AstraZeneca ↔ Merck & Co.
+ 34 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track Merck & Co. live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.